UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer

Current oncology (Toronto), 2015-02, Vol.22 (1), p.33-48

2015

Volltextzugriff (PDF)

A multicentre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer

Annals of oncology, 2020-07, Vol.31 (7), p.951-957

2020

Volltextzugriff (PDF)

Physician preferences for bone metastasis drug therapy in Canada

Current oncology (Toronto), 2015-10, Vol.22 (5), p.e342-348

2015

Volltextzugriff (PDF)

Real World Treatment Sequencing Outcomes of Endocrine-Based Targeted Combination Therapies in HR+ HER2- Advanced Breast Cancer

European journal of cancer (1990), 2018-04, Vol.92, p.S109-S110

2018

Volltextzugriff (PDF)

383 (PB-016) - Real World Treatment Sequencing Outcomes of Endocrine-Based Targeted Combination Therapies in HR+ HER2- Advanced Breast Cancer

European journal of cancer (1990), 2018-04, Vol.92, p.S109-S110

2018

Volltextzugriff (PDF)

317P Updated results from the Canadian sub-population of the phase IIIb CompLEEment-1 ribociclib + letrozole HR+ HER2- advanced breast cancer trial

Annals of oncology, 2020-09, Vol.31, p.S369-S370

2020

Volltextzugriff (PDF)

337PFirst Canadian interim analysis from the phase IIIb CompLEEment-1 ribociclib + letrozole HR+ HER2- advanced breast cancer trial

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

337P - First Canadian interim analysis from the phase IIIb CompLEEment-1 ribociclib + letrozole HR+ HER2- advanced breast cancer trial

Annals of oncology, 2019-10, Vol.30, p.v120-v120

2019

Volltextzugriff (PDF)

First Canadian interim analysis from the phase IIIb CompLEEment-1 ribociclib + letrozole HR+ HER2- advanced breast cancer trial

Annals of oncology, 2019-10, Vol.30, p.v120

2019

Volltextzugriff (PDF)

Abstract P6-18-34: Treat ER+ight Canadian prospective observational study in HR+ advanced breast cancer: 3rd interim analysis

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P6-P6-18-34

2019

Volltextzugriff (PDF)

333PRibociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial

Annals of oncology, 2019-10, Vol.30, p.v118

2019

Volltextzugriff (PDF)

333P - Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial

Annals of oncology, 2019-10, Vol.30, p.v118-v118

2019

Volltextzugriff (PDF)

Abstract P3-15-02: Treat ER+ight Canadian prospective observational study in HR+ advanced breast cancer: 2nd interim analysis

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P3-P3-15-02

2018

Volltextzugriff (PDF)

LBA87 A pragmatic cluster-randomized trial of ambulatory toxicity management in patients receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer (AToM)

Annals of oncology, 2020-09, Vol.31, p.S1214-S1214

2020

Volltextzugriff (PDF)

126P A randomized controlled trial (RCT) comparing optimal local treatment with or without endocrine therapy (ET) in patients (pts) aged ≥70 with lower risk breast cancer (BC) [REaCT-70 Study]

ESMO open, 2024-05, Vol.9, p.103114, Article 103114

2024

Volltextzugriff (PDF)

Long-term outcome after intensive therapy with etoposide, melphalan, total body irradiation and autotransplant for acute myeloid leukemia

Bone marrow transplantation (Basingstoke), 2004-06, Vol.33 (12), p.1201-1208

2004

Volltextzugriff (PDF)

Optimal systemic therapy for early breast cancer in women: a clinical practice guideline

Current oncology (Toronto), 2015-03, Vol.22 (Suppl 1), p.S67-81

2015

Volltextzugriff (PDF)

Tracheobronchial Constriction in Asthmatics Induced by Isocapnic Hyperventilation With Dry Cold Air

Chest, 1996-08, Vol.110 (2), p.404-410

1996

Volltextzugriff (PDF)

Unconventional non-amino acidic PET radiotracers for molecular imaging in gliomas

European journal of nuclear medicine and molecular imaging, 2021-11, Vol.48 (12), p.3925-3939

2021

Volltextzugriff (PDF)

Correction to: Unconventional non-amino acidic PET radiotracers for molecular imaging in gliomas

European journal of nuclear medicine and molecular imaging, 2022-05, Vol.49 (6), p.2104-2104

2022

Volltextzugriff (PDF)

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

Annals of oncology, 2014-10, Vol.25 (10), p.1979-1987

2014

Volltextzugriff (PDF)

Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study

Breast cancer research and treatment, 2014-07, Vol.146 (1), p.153-162

2014

Volltextzugriff (PDF)

Valeur prédictive des paramètres volumétriques corps entier et osseux de la 18F-FDG-TEP/TDM préthérapeutique dans la réponse au Lenvatinib chez les patients traités pour un cancer différencié de la thyroïde réfractaire à l’iode

Annales d'endocrinologie, 2020-09, Vol.81 (4), p.251-251

2020

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(27)

Sprache

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer

A multicentre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer

Physician preferences for bone metastasis drug therapy in Canada

Real World Treatment Sequencing Outcomes of Endocrine-Based Targeted Combination Therapies in HR+ HER2- Advanced Breast Cancer

383 (PB-016) - Real World Treatment Sequencing Outcomes of Endocrine-Based Targeted Combination Therapies in HR+ HER2- Advanced Breast Cancer

317P Updated results from the Canadian sub-population of the phase IIIb CompLEEment-1 ribociclib + letrozole HR+ HER2- advanced breast cancer trial

337PFirst Canadian interim analysis from the phase IIIb CompLEEment-1 ribociclib + letrozole HR+ HER2- advanced breast cancer trial

337P - First Canadian interim analysis from the phase IIIb CompLEEment-1 ribociclib + letrozole HR+ HER2- advanced breast cancer trial

First Canadian interim analysis from the phase IIIb CompLEEment-1 ribociclib + letrozole HR+ HER2- advanced breast cancer trial

Abstract P6-18-34: Treat ER+ight Canadian prospective observational study in HR+ advanced breast cancer: 3rd interim analysis

333PRibociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial

Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial

333P - Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial

Abstract P3-15-02: Treat ER+ight Canadian prospective observational study in HR+ advanced breast cancer: 2nd interim analysis

LBA87 A pragmatic cluster-randomized trial of ambulatory toxicity management in patients receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer (AToM)

126P A randomized controlled trial (RCT) comparing optimal local treatment with or without endocrine therapy (ET) in patients (pts) aged ≥70 with lower risk breast cancer (BC) [REaCT-70 Study]

Long-term outcome after intensive therapy with etoposide, melphalan, total body irradiation and autotransplant for acute myeloid leukemia

Optimal systemic therapy for early breast cancer in women: a clinical practice guideline

Tracheobronchial Constriction in Asthmatics Induced by Isocapnic Hyperventilation With Dry Cold Air

Unconventional non-amino acidic PET radiotracers for molecular imaging in gliomas

Correction to: Unconventional non-amino acidic PET radiotracers for molecular imaging in gliomas

Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study

Valeur prédictive des paramètres volumétriques corps entier et osseux de la 18F-FDG-TEP/TDM préthérapeutique dans la réponse au Lenvatinib chez les patients traités pour un cancer différencié de la thyroïde réfractaire à l’iode

Suchergebnisse filtern